A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
231actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-06 | actual | When the study began enrolling |
| Primary completion | 2025-05-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-02 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: Rocatinlimab — also filed as AMG 451
- Drug: Rocatinlimab — also filed as AMG 451
Primary outcomes
what the primary-completion date above is the date OFMaximum Plasma Concentration (Cmax) of Rocatinlimab
measured Up to approximately 112 days
Area Under the Serum Concentration-time Curve (AUC) From Time Zero to Time of Last Quantifiable Concentration (AUClast) of Rocatinlimab
measured Up to approximately 112 days
AUC From Time Zero to Infinity (AUCinf) of Rocatinlimab
measured Up to approximately 112 days
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed